Wall Street brokerages expect Eleven Biotherapeutics (NASDAQ:EBIO) to announce earnings per share (EPS) of ($0.13) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Eleven Biotherapeutics’ earnings. Eleven Biotherapeutics reported earnings per share of ($0.25) during the same quarter last year, which would suggest a positive year-over-year growth rate of 48%. The company is scheduled to issue its next quarterly earnings results on Thursday, May 3rd.
On average, analysts expect that Eleven Biotherapeutics will report full year earnings of ($0.52) per share for the current year. For the next financial year, analysts forecast that the company will post earnings of ($0.61) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that cover Eleven Biotherapeutics.
Several research analysts have commented on EBIO shares. ValuEngine raised Eleven Biotherapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. HC Wainwright set a $2.00 target price on Eleven Biotherapeutics and gave the stock a “buy” rating in a research note on Thursday.
Shares of NASDAQ EBIO opened at $1.39 on Monday. The stock has a market cap of $59.92, a price-to-earnings ratio of -1.25 and a beta of 2.97. Eleven Biotherapeutics has a 12 month low of $0.62 and a 12 month high of $2.01.
COPYRIGHT VIOLATION NOTICE: This article was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.com-unik.info/2018/04/16/0-13-eps-expected-for-eleven-biotherapeutics-ebio-this-quarter.html.
Eleven Biotherapeutics Company Profile
Eleven Biotherapeutics, Inc, a biologic oncology company, focuses on the design and development of targeted protein therapeutics (TPTs). It develops products based on its proprietary TPT platform and focused on addressing areas of unmet medical needs in cancer. The company's lead product candidates include Vicinium that is in Phase 3 clinical trial in the United States and Canada for the treatment of non-muscle invasive bladder cancer; and Proxinium for use in treating squamous cell carcinoma of the head and neck.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eleven Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.